🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

2,562 results for “Cancer” Clear

  1. PSA/IL-2/GM-CSF

    United Therapeutics Europe Ltd

    Prostate Cancer

    phase 1 mab active

    1 trial

  2. PTC299

    PTC THERAPEUTICS, INC.

    Metastatic Breast Cancer

    phase 1 small molecule completed

    1 trial

  3. PTC299

    PTC THERAPEUTICS, INC.

    Advanced Cancer

    phase 1 small molecule terminated

    1 trial

  4. PTC596

    PTC THERAPEUTICS, INC.

    Cancer

    phase 1 small molecule completed

    1 trial

  5. PV-10 (10% rose bengal disodium)

    PROVECTUS BIOPHARMACEUTICALS, INC.

    Cancer Metastatic to the Liver

    phase 1 small molecule active

    1 trial

  6. PV-10 (rose bengal disodium 10%)

    PROVECTUS BIOPHARMACEUTICALS, INC.

    Breast Cancer

    phase 1 small molecule completed

    1 trial

  7. PVSRIPO

    United Therapeutics Europe Ltd

    Invasive Breast Cancer

    phase 1 mab completed

    1 trial

  8. Paclitaxel

    Jazz Pharmaceuticals Ireland Limited

    Ovarian Cancer

    phase 1 small molecule active

    1 trial

  9. Paclitaxel

    Hospital Authority, Hong Kong

    Ovarian Cancer

    phase 1 small molecule active

    1 trial

  10. Palazestrant

    Olema Pharmaceuticals

    Metastatic Breast Cancer

    phase 1 small molecule active

    1 trial

  11. Pegfilgrastim

    Biotech Pharmaceutical Co.,

    Breast Cancer

    phase 1 small molecule completed

    1 trial

  12. Pelareorep

    ONCOLYTICS BIOTECH INC

    Breast Cancer

    phase 1 mab terminated

    1 trial

  13. Pembrolizumab

    United Therapeutics Europe Ltd

    Cervix Cancer

    phase 1 other terminated

    1 trial

  14. Pembrolizumab

    Cardiff Oncology

    Anal Cancer Stage III A

    phase 1 small molecule active

    1 trial

  15. Pemetrexed STADA 25 mg/ml Konzentrat zur Herstellung einer Infusionslösung, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Pemetrexed Fresenius Kabi 100 mg powder for concentrate for solution for infusion, Pemetrexed Fresenius Kabi 100 mg powder for concentrate for solution for infusion, KEYTRUDA 25 mg/mL concentrate for solution for infusion, RMC-6236, Cisplatinum Accord, 1 mg/ml, koncentrat do sporządzania roztworu do infuzji., CARBOPLATIN-EBEWE, 10 MG/ML, KONCENTRAT DO SPORZĄDZANIA ROZTWORU DO

    Revolution Medicines

    Lung Cancer

    phase 1 small molecule active

    1 trial

  16. Pemetrexed Synthon 25 mg/ml, concentraat voor oplossing voor infusie, DARAXONRASIB (RMC-6236), Pemetrexed Fresenius Kabi 100 mg powder for concentrate for solution for infusion, Cisplatin Hikma 1 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Carboplatin Kabi 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung, DARAXONRASIB (RMC-6236), Cisplatinum Accord, 1 mg/ml, koncentrat do sporządzania roztworu do infuzji., CISPLATIN-EBEWE, 1 MG/ML, KONCENTRAT DO SPORZĄDZANIA ROZTWORU DO INFUZJI, Pemetre

    Revolution Medicines

    Lung Cancer

    phase 1 small molecule active

    1 trial

  17. Ph 1 Study of ORIC-944 in Patients with Metastatic Prostate Cancer.

    Topiloric/Uriadec

    Prostate cancer

    phase 1 other active

    1 trial

  18. Phase 1 First in Human Study to Explore AMG 355 as Monotherapy and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors

    Amgen

    Dose Escalation: Non-small cell lung cancer (NSCLC), colorectal cancer (CRC), gastric cancer (GC), melanoma (MEL). Dose Confirmation: Lead Indication based on data from dose escalation. Dose Expansion: Tertiary Lymphoid Structure positive (TLS+) CRC, GC, and NSCLC.

    phase 1 other active

    1 trial

  19. Phase 1 Study of AMG 509 in Subjects With Metastatic Castration-Resistant Prostate Cancer

    Amgen

    Metastatic Castration-Resistant Prostate Cancer (mCRPC)

    phase 1 other active

    1 trial

  20. Phase 1 Study of AZD9833 Alone or in Combination in Women with Advanced Breast Cancer

    AstraZeneca AB

    "Estrogen Receptor Positive HER2 Negative Advanced Breast Cancer"

    phase 1 other active

    1 trial

  21. Phase 1 Study of IMC-P115C in Advanced PRAME Positive Cancers

    Immunocore Ireland Limited

    Advanced PRAME Positive Cancers

    phase 1 other active

    1 trial

  22. Phase 1 Study of JNJ-89402638 for Metastatic Colorectal and Gastric Cancer

    Janssen-Cilag International N.V.

    Metastatic colorectal cancer and Gastric cancer

    phase 1 other active

    1 trial

  23. Phase 1 dose-escalation trial of OMTX705, an anti-fibroblast activation protein antibody-drug conjugate, as single agent and in combination with anti-PD-1 or pazopanib in patients with advanced solid tumors

    Lacuna Pharma Pty Ltd

    Selected tumor indications that are known to express FAP (Fibroblast activation protein) either on tumor stroma CAFs (Cancer-associated fibroblasts) (carcinomas) or on tumor cells (leiomyosarcomas and other sarcomas).

    phase 1 other active

    1 trial

  24. Phase 1 trial of valemetostat and darolutamide in mCRPC

    Daiichi Sankyo

    Metastatic Castration Resistant Prostate Cancer (mCRPC)

    phase 1 other active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources